[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lower-risk-myelodysplastic-syndromes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lower-risk-myelodysplastic-syndromes":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100641405",false,"NCT07653581","rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia","rhTPO + CsA Versus CsA Alone in the Treatment of Lower-risk MDS With Thrombocytopenia: a Single-center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Confirmed diagnosis of lower-risk MDS;\n3. Platelet ≤ 30×109\u002FL, or \\\u003C 50×109\u002FL and accompanied by bleeding events;\n4. Baseline liver and kidney functions \\\u003C2 ULN;\n5. Signed the informed consent form;\n6. ECOG 0-2;\n\nExclusion Criteria:\n\n1. History of leukemia or stem cell transplantation, treatment-related MDS or malignant tumors;\n2. With splenomegaly or myelofibrosis;\n3. Infections or bleeding that cannot be controlled by standard treatment;\n4. Any concurrent malignant tumors within the past 5 years, or basal cell carcinoma of the skin at the local site;\n5. History of thromboembolic events, heart attack or stroke and current use of anticoagulants;\n6. Previously received cyclosporine (CsA) or ATG within 6 months;\n7. Previously used IL-11, rhTPO or TPO-RA;\n8. Pregnant or lactating women;\n9. Participated in other clinical trials within 3 months.","ALL","18 Years",{"count":18,"type":19},78,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.",[25],"Lower-risk Myelodysplastic Syndromes","NOT_YET_RECRUITING","2026-06-11",{"date":29,"type":30},"2026-06-17","ACTUAL",{"date":32,"type":19},"2026-06",{"date":34,"type":19},"2029-12",{"name":36,"class":37},"Peking Union Medical College Hospital","OTHER",""]